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Two members of the paramyxovirus family, Nipah virus (NiV) and Hendra virus (HeV), are recent additions
to a growing number of agents of emergent diseases which use bats as a natural host. Identification of
ephrin-B2 and ephrin-B3 as cellular receptors for these viruses has enabled the development of immunother-
apeutic reagents which prevent virus attachment and subsequent fusion. Here we present the structural
analysis of the protein and carbohydrate components of the unbound viral attachment glycoprotein of NiV
glycoprotein (NiV-G) at a 2.2-Å resolution. Comparison with its ephrin-B2-bound form reveals that confor-
mational changes within the envelope glycoprotein are required to achieve viral attachment. Structural
differences are particularly pronounced in the 579–590 loop, a major component of the ephrin binding surface.
In addition, the 236–245 loop is rather disordered in the unbound structure. We extend our structural
characterization of NiV-G with mass spectrometric analysis of the carbohydrate moieties. We demonstrate that
NiV-G is largely devoid of the oligomannose-type glycans that in viruses such as human immunodeficiency
virus type 1 and Ebola virus influence viral tropism and the host immune response. Nevertheless, we find
putative ligands for the endothelial cell lectin, LSECtin. Finally, by mapping structural conservation and
glycosylation site positions from other members of the paramyxovirus family, we suggest the molecular surface
involved in oligomerization. These results suggest possible pathways of virus-host interaction and strategies for
the optimization of recombinant vaccines.
The emergence of highly virulent pathogens from previously
undisturbed ecological niches is considered an increasing
threat (58). This is exemplified by the recent emergence
throughout Southeast Asia and Australia of Nipah virus (NiV)
and Hendra virus (HeV), zoonotic paramyxoviruses character-
ized by high mortality rates. Outbreaks of these viruses origi-
nate from the fruit bat and are usually triggered by contami-
nation of food and water or by direct contact with infected
animals (39). NiV was first detected in 1998 in Malaysia, where
it was transmitted from pigs to humans and resulted in the
culling of over 1 million pigs to contain the outbreak (39). The
first outbreak of HeV occurred in 1994 in the Brisbane
suburb of Hendra, Australia, where infected horses trans-
mitted the virus to humans (18, 52). Symptoms of infection
for both of these viruses include acute encephalitis and
respiratory illness, and the time from onset to death is
usually 7 to 10 days. Due to their high mortality rates and
rapid emergence, NiV and HeV have been designated bio-
safety level 4 pathogens by the Centers for Disease Control
and Prevention (Atlanta, GA).
NiV and HeV are enveloped, single-stranded, negative-
sense RNA viruses which constitute the Henipavirus (HNV)
genus in the Paramoxyviridae family. Henipaviruses enter their
host cell by a pH-independent mechanism utilizing two outer
membrane proteins: HNV-G for cell attachment and HNV-F
for fusion. NiV-G and HeV-G are oligomeric type II trans-
membrane glycoproteins composed of an N-terminal cytoplas-
mic tail (approximately 50 amino acids), a transmembrane
domain (23 amino acids), a stalk region (110 amino acids), and
a C-terminal globular head domain (approximately 420 amino
acids). Analytical ultracentrifugation and size exclusion chro-
matography have demonstrated that the NiV-G ectodomain is
predominantly tetrameric, although some lower-order species
were also observed (7). On the virion surface, HNV-G associ-
ates with HNV-F through the stalk region, facilitating entry
into the host (19).
Unlike the closely related parainfluenza viruses (PIVs) and
Newcastle disease virus (NDV), which enter their hosts via
sialic (neuraminic) acid-mediated attachment, henipaviruses
use ephrin-B2 (EFNB2) and EFNB3 cell surface glycoproteins
as high-affinity functional receptors (4, 44, 45). This correlates
with the broad tissue tropism of these viruses, since ephrins are
widely expressed in neurons, bone, stem cells, and epithelial
cells and across the immune system and are used in many
signaling processes underlying axon guidance, vascular devel-
opment, and osteogenesis (31, 49). In addition, the ability of
these viruses to infect a wide range of hosts is reflected in the
broad species conservation of the ephrin ligands, which are
expressed and well conserved (95% sequence identity) in
many vertebrates, including bats, horses, and pigs (6). Recent
crystal structures of NiV-G and HeV-G in complex with
* Corresponding author. Mailing address: Division of Structural Bi-
ology, University of Oxford, Henry Wellcome Building of Genomic
Medicine, Roosevelt Drive, Oxford OX3 7BN, United Kingdom.
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EFNB2 revealed a highly conserved binding mode (7). Vacci-
nation with recombinant HNV-G in animal models generates a
neutralizing antibody response to protein surfaces utilized for
henipavirus attachment (5, 22). These neutralizing antibodies
can provide passive immunity to henipavirus (23, 62). The
structural similarity of EFNB2 binding by NiV-G and HeV-G
underscores the potential for the development for a single
vaccine that protects against challenge from both viruses (5, 7).
Encouragingly, recombinant HeV-G can protect against NiV
infection in cats (42).
The use of proteins as functional receptors for host attach-
ment within the Paramyxoviridae is not limited to henipavi-
ruses. Morbillaviruses such as measles, canine distemper, and
rinderpest viruses have recently been shown to require SLAM
(CD151) for viral attachment (59). Structure-based phyloge-
netic analysis, however, shows that HNV-G is structurally more
similar to attachment glycoproteins of sialic acid binding vi-
ruses such as NDV and PIVs (37, 60) than to that of measles
virus (MV) (7, 12, 29), suggesting that the protein binding
capacities of henipaviruses and morbilliviruses have evolved
independently.
While the crystal structures of NiV-G and HeV-G in com-
plex with EFNB2 reveal an interface dominated by protein-
protein interactions, the carbohydrate moieties of many viral
envelope glycoproteins can influence tissue tropism through
interaction with host cell surface lectins (8), increasing the
concentration of the virus at the cell surface and colocalizing it
with cell attachment proteins. The -propeller domain of
NiV-G contains five N-linked glycosylation sequons (NXS/TX,
where X is any amino acid except proline). N-linked glycosyl-
ation occurs in the endoplasmic reticulum and, through the
calnexin/calreticulin folding pathways, can be critical for pro-
tein folding and expression (48). For mammalian glycopro-
teins, the immature oligomannose-type glycans are usually pro-
cessed to complex-type structures in the Golgi apparatus (33).
However, processing of viral glycosylation is not always com-
plete, and many enveloped viruses contain immature oligo-
mannose-type glycans. Oligomannose-type glycans are largely
absent from the host cell surface (8), and their presence on
pathogens can be a signal to the host immune system through
recognition by serum and cell surface lectins (8). For example,
in human immunodeficiency virus type 1 (HIV-1), a cluster of
oligomannose-type glycans promotes infection through inter-
action with the C-type lectin DC-SIGN (8). Such oligoman-
nose-type glycans can also upregulate the host immune re-
sponse by activating the complement cascade through
interaction with the serum mannose binding protein. Further-
more, oligomannose-type glycans can act as ligands for the
macrophage mannose receptor, promoting antigen presenta-
tion. This mannose receptor targeting can be exploited in the
optimization of vaccines (32).
To facilitate the development of antiviral drugs, we deter-
mined the crystal structure of the unbound globular domain of
NiV-G. Furthermore, we extended our structural analysis of
NiV-G with mass spectrometric (MS) analysis of the carbohy-
drate moiety. Together with mapping of the glycosylation sites
from across the paramyxoviruses, our analyses suggest strate-
gies for the optimization of recombinant vaccines.
MATERIALS AND METHODS
Protein expression and purification. NiV-G (residues 183 to 602, GenBank
accession number NC_002728; synthesized by GeneArt, Regensburg, Germany)
was expressed and purified as previously described (7). Briefly, cDNA was cloned
into the pHLsec vector (1) and transiently expressed in human embryonic kidney
(HEK) 293T cells in the presence of the class I -mannosidase inhibitor, kifu-
nensine (Toronto Research Chemicals, Ontario, Canada) (9), using 2 mg DNA
per liter cell culture. Protein was purified by immobilized metal affinity chroma-
tography and then treated with endoglycosidase F1 (75 g mg1 protein, 12 h,
21°C) to release the N-linked glycans (see Fig. S1 in the supplemental material).
Following partial deglycosylation, protein complexes were purified by size exclu-
sion chromatography using a Superdex 200 10/30 column (Amersham, United
Kingdom), in 150 mM NaCl–10 mM Tris (pH 8.0) buffer. Typical protein yields
were about 2 mg of pure, deglycosylated NiV-G per liter cell culture.
Crystallization and structure determination. Crystals were grown by sitting-
drop vapor diffusion using 100 nl protein plus 100 nl precipitant as described
previously (56). NiV-G crystals grew at 4°C (6.5 mg ml1) in 20% (vol/vol)
polyethylene glycol 6000, 0.1 M MES (morpholineethanesulfonic acid) (pH 6.0),
0.1 M LiCl, and 18% -butylactone after 3 days. Crystals were flash frozen by
immersion in a cryoprotectant containing 25% (vol/vol) ethylene glycol followed
by rapid transfer to a gaseous nitrogen stream. Data were collected at beamline
ID23-2 at the European Synchotron Radiation Facility, Grenoble, France. Im-
ages were integrated and scaled using the programs DENZO and SCALEPACK
(46). Details are presented in Table 1.
The structure of NiV-G was solved by molecular replacement using the pro-
gram Phaser (41) with the NiV-G component of the NiV-G–EFNB2 complex
(PDB accession number 2VSM) as the search model. Two molecules were
identified in the asymmetric unit. Structure refinement was performed using
Refmac 5 in the CCP4 suite and included iterative restrained refinement with
TABLE 1. NiV-G crystallographic and structural data
Parameter (unit) Valuea
Data collection
Resolution (A˚) .......................................................40.0–2.25
Space group ............................................................P21
Cell dimensions (A˚) and angles (°) .....................a  71.6, b  86.9,
c  82.9,  
90,   108.3,
  90
No. of unique reflections ......................................45,810 (4,555)
Completeness (%) .................................................100 (100)
Rmerge (%)
b .............................................................8.6 (52.5)
I/	I ...........................................................................18.4 (3.1)
Avg redundancy .....................................................7.3 (5.8)
Refinement
Resolution range (A˚) ............................................40.0–2.25
No. of reflections ...................................................43,463
Rfactor (%)
c ..............................................................17.2
Rfree (%)
d ................................................................22.1
RMSDe
Bonds (A˚) ...........................................................0.008
Angles (°) ............................................................1.2
Main-chain bond (A˚2) .......................................0.6
Side-chain bond (A˚2).........................................0.7
Between noncrystallographic symmetry-
related C atoms (A˚) ....................................0.6
Atoms per asymmetric unit (protein/water).......6,510/579
Avg B-factors (protein/water) (A˚2)......................26.7/32.9
a Numbers in parentheses refer to the relevant outer resolution shell.
b Rmerge  
hkl 
i I(hkl;i)  I(hkl) /
hkl 
iI(hkl;i), where I(hkl;i) is the
intensity of an individual measurement and I(hkl) is the average intensity
from multiple observations.
c Rfactor  
hklFobs  k Fcalc/
hkl Fobs .
d Rfree is Rfactor for 5% of the data not used at any stage of the structural
refinement.
e RMSD, RMS deviation from ideal geometry.
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TLS using medium noncrystallographic symmetry restraints between the two
NiV-G molecules in the asymmetric unit (25, 43). The program COOT was used
for manual rebuilding (17), and PROCHECK and Molprobity were used to
validate the model (36, 38). Ramachandran analysis (36) of the final structure
showed 84% of residues in the most favored region, with no residues in disal-
lowed regions.
Molecular superimpositions were calculated using SHP (54). Sequence align-
ments were prepared with Multalign (13) and Espript (20). Figures were pre-
pared using Adobe Photoshop and Pymol (http://pymol.sourceforge.net).
Enzymatic release of N-linked glycans for MS. Glycans were released by the
method of Ku¨ster et al. (35). Coomassie blue-stained sodium dodecyl sulfate-
polyacrylamide gel electrophoresis bands containing approximately 10 g of
target NiV-G were excised, washed with 20 mM NaHCO3 (pH 7.0), and dried in
a vacuum centrifuge before rehydration with 30 l of 30 mM NaHCO3 (pH 7.0)
containing 100 U ml1 of protein N-glycanase F (Prozyme, San Leandro, CA).
After incubation for 12 h at 37°C, the enzymatically released N-linked glycans
were eluted with water and the sample was passed through a 0.45-l-pore-size
filter (Millex-LH, hydrophobic polytetrafluoroethylene).
MALDI-TOF MS. Positive-ion matrix-assisted laser desorption ionization–
time-of-flight (MALDI-TOF) mass spectra of glycans were generated according
to previously described methods (28). Spectra were recorded with a Waters-
Micromass TofSpec 2E reflectron-TOF mass spectrometer (Waters-MS Tech-
nologies, Manchester, United Kingdom) operated under the following condi-
tions: accelerating voltage, 20 kV; pulse voltage, 3.0 kV; time lag focusing delay,
500 ns (setting 39); laser repetition rate, 10 Hz. Aqueous glycan samples (0.5 l)
were mixed on the MALDI target with the matrix (0.5 l of a saturated solution
of 2,5-dihydroxybenzoic acid in acetonitrile), allowed to dry under ambient
conditions, and recrystallized from ethanol (0.2 l).
Negative-ion nano-electrospray MS/MS. Electrospray MS was performed with
a Waters quadrupole-time-of-flight (Q-Tof) Ultima Global instrument in nega-
tive-ion mode according to previously described methods (26–28). Samples in 1:1
(vol/vol) methanol-water were infused through Proxeon nanospray capillaries
(Proxeon Biosystems, Odense, Denmark). The ion source conditions were as
follows: temperature, 120°C; nitrogen flow 50 liters h1; infusion needle poten-
tial, 1.2 kV; cone voltage 100 V; RF-1 voltage, 150 V. Spectra (2-s scans) were
acquired with a digitization rate of 4 GHz and accumulated until a satisfactory
signal/noise ratio had been obtained. For MS/MS data acquisition, the parent ion
was selected at low resolution (about 5 m/z mass window) to allow transmission
of isotope peaks and fragmented with argon at a pressure of 50 Pa. The voltage
on the collision cell was adjusted to give an even distribution of fragment ions
across the mass scale. Typical values were 80 to 120 V. Other voltages were as
recommended by the manufacturer. Instrument control, data acquisition, and
processing were performed with MassLynx software version 4.0.
Protein structure accession number. Coordinates and structure factors of
NiV-G have been deposited in the Protein Data Bank (PDB accession number
2VWD).
RESULTS AND DISCUSSION
Structure of unbound NiV-G. The globular six-bladed -pro-
peller domain (residues 183 to 602) of the NiV-G envelope
glycoprotein was transiently expressed in HEK 293T cells in
the presence of kifunensine and partially deglycosylated with
endoglycosidase F1 (see Fig. S1 in the supplemental material).
FIG. 1. Crystal structure of apo-NiV-G reveals an induced-fit mechanism for EFNB2 binding. (A) C trace of apo-NiV-G (orange, chain A;
dark blue, chain B) superimposed with NiV-G of the NiV-G–EFNB2 complex (cyan; PDB accession number 2VSM [7]). (B) Relative B-factor
values (ramped from blue to red) mapped onto the C trace structure of apo-NiV-G (chain B). Mobile regions have a thick radius and are colored
red (high B-factor), while ordered regions have a thin radius and are colored blue (low B-factor). The -propellers are numbered according to
standard nomenclature (7, 14, 37, 60). (C) RMS displacement of equivalent residues between apo-NiV-G (average of chains A and B) and
EFNB2-bound NiV-G mapped onto C trace structure of apo-NiV-G (chain B). The tube radius and color of the trace represent the RMS
displacement (ramped from blue to red). Regions with high deviations between apo and EFNB2-bound forms are thick and colored red, while
regions with low deviation are thin and colored blue. The gray region indicates the surface of the protein that interacts with EFNB2. (D) RMS
displacement between NiV-G bound EFNB2 and the other reported EFNB2 structures mapped onto the C trace structure of NiV-G-bound
EFNB2 (average of apo-EFNB2 [55], EPHB2-EFNB2 [30], and EPHB4-EFNB2 [11]; colored as in panel C). The gray region indicates the surface
of the protein that interacts with NiV-G.
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We have previously demonstrated by analytical ultracentrifu-
gation that this recombinant form of NiV-G is monomeric (7).
The domain was crystallized and the structure determined at
2.2-Å resolution by molecular replacement (Table 1 and Fig.
1). The two molecules in the crystallographic asymmetric unit,
chains A and B, are, with the exception of the 579–590 loop
(see below), mostly very similar to each other (root mean
square [RMS] deviation in C position of 0.6 Å) and to the
structure of the EFNB2-bound form (RMS deviation of 1.0
and 0.7 Å over 410 equivalent C atoms for chains A and B,
respectively) (Fig. 1A and C). NiV-G is also quite similar to the
hemagglutinins of PIV type 3 (PIV3-HN) (PDB accession
number 1V2I [37]; RMS deviation of 2.3 Å over 380 equivalent
C atoms), NDV (NDV-HN) (1E8T [10]; RMS deviation 2.4
Å over 372 equivalent C atoms), simian PIV5 structures
(SV5-HN) (1Z4V [60]; RMS deviation of 2.4 Å over 368 equiv-
alent C atoms), and HeV (HeV-G) (2VSK [7]; RMS devia-
tion of 0.8 Å over 397 equivalent C atoms) but much less
similar to the MV hemagglutinin (MV-H) (2RKC [12, 29];
RMS deviation of 3.3 Å over 320 equivalent C atoms). This is
consistent with our previously published hypothesis that
paramyxoviruses have adapted to attach to proteins rather
than sugars in at least two separate evolutionary events (7).
Specificity of NiV-G binding. Both molecules in the crystal-
lographic asymmetric unit of apo-NiV-G show structural dif-
ferences from the EFNB2-bound form in the region of the
579–590 loop. In the NiV-G–EFNB2 and HeV-G–EFNB2
complexes (PDB accession numbers 2VSM and 2VSK, respec-
tively), this loop is critical for complex formation (7). Specifi-
cally, Ile588NiV-G and Tyr581NiV-G participate in hydrophobic
interactions and contribute to a binding pocket that accommo-
dates Phe120EFNB2 (Fig. 2A). Consistent with these observa-
tions, mutagenesis experiments have indicated the importance
of this residue in receptor binding (7). In the unbound form of
NiV-G, the 579–590 loop is relatively flexible in both molecules
of the crystallographic asymmetric unit, and 2Fo-Fc electron
density for the side chains is poor. Nevertheless, continuous
electron density is visible for the main chain, which is displaced
by up to 6 Å (chain B) from its EFNB2-bound position. In both
molecules in the crystallographic asymmetric unit, the 579–590
loop participates in crystal packing, perhaps explaining their
different conformations. The loop structure in both of these
molecules precludes EFNB2 binding with movement required
to accommodate Phe120EFNB2 (Fig. 2A, B, and C). In addition,
the 579–590 and 236–245 loops exhibit high B-factor values in
the apo form (Fig. 1B and C). Interestingly, these loops ac-
count for only 22% of the total buried surface in the NiV-G-
EFNB2 binding interface (34). The rest of the NiV-G surface
is far more structurally conserved between the apo and com-
plexed forms. We previously identified the Phe120EFNB2 bind-
ing pocket as a potential template for structure-based drug
design (7). The structure of the apo form of NiV-G, reported
here, further refines this potential drug target by highlighting
the structural plasticity of this pocket.
The flexibility of apo-NiV-G in the region of the 579–590
and 236–245 loops is mirrored in the complementary binding
face of the EFNB2 structures (Fig. 1D) (7, 11, 30, 55). Com-
parison of the NiV-G-bound EFNB2 with apo-EFNB2 (PDB
accession number 1IKO) and EFNB2 in complex with the
cellular receptors EPHB2 (1NUK) and EPHB4 (2HLE) re-
veals that residues in the GH loop (Glu119 to Leu127) exhibit
relatively high structural deviations (Fig. 1D). Thus, opposing
loops of both NiV-G and EFNB2 undergo induced-fit confor-
mational changes upon binding.
Monomeric NiV-G contains processed complex-type glyco-
sylation. Within the NiV-G crystal structure, electron density
for N-acetylglucosamine (GlcNAc) 1-linked to Asn was ob-
served at all five predicted N-linked glycosylation sites
(Asn306, Asn378, Asn417, Asn481, and Asn529) (Fig. 3A; see
Fig. S2 in the supplemental material). The presence of a single
GlcNAc at each glycosylation site is consistent with full occupancy
and effective cleavage of the kifunensine-induced oligomannose-
type glycans by endoglycosidase F1 (9). Most GlcNAc residues
project away from the protein surface with little carbohydrate-
protein interaction, as illustrated for Asn378 in Fig. 3B. However,
the GlcNAc at Asn306 packs against the aromatic side chain of
Tyr309 (Fig. 3C). The hydrophobic faces of reducing-terminal
GlcNAc residues are often found in contact with aromatic resi-
dues, effectively shielding hydrophobic patches on the protein
surface (50).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
analysis reveals that recombinant NiV-G (residues 183 to 602,
expressed in HEK 293T cells) comprises between 15 and 30%
carbohydrate (see Fig. S1 in the supplemental material). The
FIG. 2. Conformational plasticity of the EFNB2 binding pocket of NiV-G. (A) When bound to EFNB2, NiV-G residues Gln559, Glu579,
Tyr581, and Ile588 (stick representation with nitrogen blue, oxygen red, and carbon white) form a pocket around Phe120EFNB2 (gray van der Waals
surface; stick representation with nitrogen blue, oxygen red, and carbon yellow). (B and C) Superimposed Phe120EFNB2 is no longer accommodated
in the apo structure of chain B (B) or chain A (C) in the asymmetric unit of NiV-G due to steric clashes resulting from 579–590 loop movements.
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processing of glycosylation can be influenced by both tissue-
specific factors, such as glycosyltransferase expression, and
protein structure (53). Consequently, only limited conclusions
can be drawn from the carbohydrate analysis of recombinant
material. However, the occurrence of oligomannose-type gly-
cans can indicate glycosylation sites that are sterically pro-
tected from processing (2, 8, 16); such glycans are often con-
served between infectious virions and recombinant material.
For example, the mannose epitope of a broadly neutralizing
antibody to HIV-1 gp120 is independent of oligomerization
state and is present in recombinant gp120 monomers expressed
in CHO cells (8, 61). Furthermore, in direct comparison with
our present study, we note that MS analysis of the surface
glycoprotein of Ebola virus by Powlesland et al. also exploited
recombinant expression in HEK 293T cells (51). Therefore,
with the caveat that the envelope glycoprotein under investi-
gation is monomeric, we investigated whether oligomannose-
type glycans and other lectin targets were present in NiV-G.
We determined the composition of the carbohydrate compo-
nent of recombinant NiV-G (expressed in HEK 293T cells in
the absence of kifunensine) by MALDI-TOF MS and assigned
structural isomers by negative-ion nano-electrospray MS/MS
(26–28) (data not shown) of purified glycans released by in-gel
protein N-glycanase F. Glycan structures are shown in Fig. 4A
and in Table S1 in the supplemental material.
In contrast to the case for other enveloped viruses, such as
HIV-1 (61) and Ebola virus (40, 51), NiV-G contains highly
processed complex-type glycans with negligible levels of oligo-
mannose-type glycans terminated with Man132Man motifs
(Fig. 4A). This is consistent with viral tropism mediated by
protein-protein-type interaction with ephrin rather than bind-
ing via oligomannose-specific lectins such as DC-SIGNR (24).
The processing to complex-type glycosylation is consistent with
the accessibility and lack of clustering of the positions of the
glycosylation sites in the crystal structure of the monomer. The
GlcNAc132Man terminal structures in NiV-G are similar to
those reported to exist on the Ebola virus surface glycoprotein.
In Ebola virus, these structures mediate binding to the C-type
lectin, LSECtin, expressed on sinusoidal endothelial cells of
lymph nodes and liver (51). These carbohydrate motifs are
common but not ubiquitous on viral surfaces. For example,
LSECtin also binds to the S protein from severe acute respi-
ratory syndrome coronavirus, whereas in contrast, hepatitis C
virus pseudovirions and HEK 293T-derived HIV-1 virions do
not interact with LSECtin (21). Therefore, despite the inherent
limitations of recombinant systems, the effect of differential
viral glycosylation on receptor binding can be revealed by com-
parison of material from matched expression systems. We sug-
gest that NiV binding to host lectins, such as LSECtin, may
influence viral infectivity and that based on our observations,
an analysis of the glycosylation of native oligomeric NiV-G
from primary isolates would be of significant interest.
We also determined the glycosylation status of the NiV-G
expressed in the presence of kifunensine, generated for crys-
tallization (9), revealing a series of endoglycosidase F1-sensi-
tive oligomannose-type glycans ranging from Man9GlcNAc2
(m/z 1905.7) to a trace amount of Man5GlcNAc2 detectable at
m/z 1257.2 (Fig. 4B), consistent with previous MALDI MS
analysis of the effect of glycan processing by kifunensine (8, 9,
15). Comparison of the spectra in Fig. 4A and B supports our
conclusion that NiV-G is largely devoid of oligomannose-type
glycans. The paucity of these structures suggests that glycosyl-
ation engineering of vaccines based on recombinant NiV-G, to
induce oligomannose-type glycosylation, may be a route by
which to enhance immunogenicity, increasing the uptake of the
vaccine by macrophages (32).
Mapping the putative oligomeric face of NiV-G. Previously
reported analysis of the full-length NiV-G ectodomain, by an-
alytical ultracentrifugation, demonstrated that it was mainly
tetrameric (7). Similarly, gel filtration of HeV-G revealed
monomers, dimers, and tetramer (5). Oligomerization of
NiV-G, by analogy with the NDV, is likely to be induced by
interchain disulfide bonds within the stalk region, which is
absent in our NiV-G crystal structure. However, the overall
FIG. 3. NiV-G N-linked glycosylation sites. (A) Cartoon representation of NiV-G (chain B) with GlcNAc1-Asn structures shown in sticks. The
carbons of GlcNAc are shown in green, while those of side chains are colored gray. Oxygen atoms are colored red, and nitrogen atoms are blue.
A simulated annealing electron density omit map calculated in the absence of carbohydrate is displayed around the GlcNAc residues contoured
at 1	. (B and C) Enlarged views of the GlcNAc residue at Asn378 (B) and the GlcNAc residue at Asn306 (C); the omit map was calculated in
the absence of carbohydrate and Asn378, Asn306, and Tyr309.
11632 BOWDEN ET AL. J. VIROL.
 o
n
 M
ay 22, 2014 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
architecture of the oligomeric assembly remains unknown. We
sought to infer the oligomeric architecture of NiV-G by com-
paring structural features of homologous proteins across the
paramyxovirus family.
While the largest intermolecular interface in the NiV-G
crystal occludes only 600 Å2 of surface (34), inconsistent with
oligomerization, packing interactions of the -propeller do-
mains in the crystal structures of SV5-HN, NDV-HN, and
human PIV3-HN revealed dimeric and tetrameric arrange-
ments (14, 37, 60). The structure of human PIV3-HN demon-
strates that the detection of oligomeric states within the crystal
lattice is not necessarily precluded by the absence of the stalk
domain. However, Yuan et al. suggested a putative oligomer-
ization face of the envelope attachment glycoproteins of the
Paramyxovirus family through the identification of regions of
low structural diversity by superimposition of the available
crystal structures of hemagglutinins from SV5, NDV, and PIV3
(60). We extend this analysis by including our NiV-G structure
and find significant structural divergence along the face formed
by the propeller blades 2 to 4 and structural similarity on the
opposing face (Fig. 5A), consistent with the previous study
(60), suggesting that the region of the propeller blades 1 and
6 of the NiV-G forms the putative oligomerization face. In-
terestingly, a further region of low structural diversity cor-
responds to the ephrin binding face of NiV-G (Fig. 5B).
We further extend the analysis of the putative oligomeriza-
tion face by considering the conservation of N-linked glycosyl-
ation sites across the Paramyxoviridae family. Our MS analysis
demonstrated that over 2 kDa of carbohydrate may be at-
tached to individual glycosylation sites on NiV-G (Fig. 4B).
Such large and highly heterogeneous groups are generally not
found on protein surfaces utilized for protein-protein interac-
tions. To map the putative oligomeric face of NiV-G, we
aligned sequences of the envelope glycoprotein from viruses
across the paramyxovirus family and mapped the positions of
the glycosylation sites onto the structure of apo-NiV-G (Fig.
5C and D). Inspection of Fig. 5C and D reveals significant
diversity in the positions of the glycosylation sites. The low
degree of glycosylation site conservation (see Fig. S4 in the
supplemental material) suggests that there are no conserved
structural roles for individual glycans, although the retention
of glycosylation sites at nonspecific sites across the structure is
consistent with a general role in chaperone-mediated protein
folding. However, analysis reveals that the 1 and 6 propeller
blades, which were identified above as a region of low struc-
tural divergence, are largely devoid of N-linked glycans. The
FIG. 4. MS analyses of NiV-G monomer, showing MALDI-TOF MS of N-linked glycans released by in-gel protein N-glycanase F digestion.
(A) Spectra of [M  Na] ions of N-linked glycans from the NiV-G expressed in HEK 293T cells. (B) Spectra of [M  Na] ions of glycans from
NiV-G expressed in HEK 293T cells in the presence of 5 M kifunensine. Symbols used for the structural formulae: , Gal; }, GalNAc; f,
GlcNAc; E, Man; , sialic acid; ß, Fuc. The linkage position is shown by the angle of the lines linking the sugar residues (vertical line, 2-link;
forward slash, 3-link; horizontal line, 4-link; back slash, 6-link). Anomericity is indicated by full lines for -bonds and broken lines for -bonds.
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small number of glycosylation sites within this region are lo-
cated at the membrane-proximal and distal faces of the glyco-
protein and are not anticipated to disrupt lateral interactions
(Fig. 5D).
The suggestion that the surface of the 1 and 6 propeller
blades forms the oligomerization face of NiV-G is further
supported by the observation that this face mediates dimeriza-
tion of SV5, PIV3, and NDV hemagglutinin neuraminidases
(37, 60). The positions of the glycosylation sites on NiV-G are
consistent with a model of the tetramer based on the crystal
structure of the SV5 hemagglutinin (data not shown).
Structural guide to vaccine and antiviral drug design. It is
now evident that the use of ephrins as functional receptors
defines the tropism of henipaviruses. We have demonstrated
that both EFNB2 and NiV-G undergo conformational changes
upon binding. These conformational changes underscore the
importance of structural analysis of the apo and bound forms
of an interaction pair for structure-based drug design. The
NiV-G–EFNB2 interface is characterized by pockets that ac-
commodate hydrophobic residues from EFNB2, most notably
Trp125EFNB2 and Phe120EFNB2 (7). In light of recent advances
in the identification of small-molecule antagonists which dis-
rupt protein-protein interfaces exhibiting inherent structural
plasticity (57), we anticipate that this deep hydrophobic groove
of NiV-G, and in particular the structurally malleable
Phe120EFNB2 binding pocket, is a tractable drug target.
Our analysis of the glycosylation status and N-linked glyco-
sylation site conservation of recombinant NiV-G suggests that
these carbohydrate structures provide a route for further op-
timization of recombinant vaccines against NiV. The HeV
vaccine candidate, consisting of the full-length ectodomain of
HeV-G, is a heterogeneous mixture of oligomers (5). The
presentation of the oligomeric interface in a heterogeneous
vaccine may lead to antibody responses toward the nonneu-
tralizing epitopes. As oligomeric proteins generally have
greater immunogenicity than monomeric constructs (3), struc-
ture-guided stabilization of the tetramer may be a route to
vaccine optimization. Alternatively, the “immunofocusing” ap-
proach of Pantophlet and Burton (47), in which additional
N-linked glycosylation sites are added to nonneutralizing
epitopes, could be used to generate a homogenous monomer
that directs a neutralizing antibody response toward the ephrin
binding face. For such an approach, the positions of the addi-
tional glycosylation sites could be guided by the locations of
sites in related paramyxoviruses (Fig. 5C and D; see Fig. S3 in
the supplemental material) as well as by the putative oligomer-
ization face.
Finally, our glycosylation analysis demonstrated putative li-
gands for the epithelial lectin, LSECtin, and revealed a paucity
of oligomannose-type glycans on recombinant NiV-G. In con-
trast, our expression system for crystallographic analysis of
glycoproteins using an -mannosidase inhibitor exhibits uni-
FIG. 5. Conservation of N-linked glycosylation sites on NiV-G across paramyxoviruses. (A) Cartoon representation (C trace) of the crystal
structures of the globular -propeller domains from envelope attachment glycoproteins of NiV-G (gray; PDB accession number 2VSM), NDV-HN
(pink; 1E8T), PIV3-HN (green; 1V2I), and SV5-HN (blue; 1Z4Y). (B) Residues from the G-H loop of EFNB2 (sticks; residues 115 to 127) in
complex with NiV-G (van der Waals surface), where sticks are colored yellow for carbon, blue for nitrogen, and red for oxygen. The surface is
colored by a gradient of red (completely buried) to white (not buried) according to the fraction of buried surface area. (C) Superimposition of C
trace ribbon of NiV-G with N-linked glycosylation sites of NiV-G, HeV-G, PIV1, PIV2, PIV3, Sendai virus, and NDV mapped as spheres at the
C on equivalent residues. The position of the NiV-G glycans (at Asn306, Asn378, Asn417, Asn481, and Asn529) are indicated by orange spheres,
and the positions of glycans from the other viruses are indicated by yellow spheres. (D) View of NiV-G formed by a 90° rotation of panel C. The
putative oligomerization face is indicated by a blue bracket.
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formly oligomannose-type glycosylation. Such mannose-based
expression systems may find utility in the development of re-
combinant henipavirus vaccines by stimulating mannose-de-
pendent uptake by antigen-presenting cells (32).
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